skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In the developing pharma landscape, it’s important to consider all variables to create a winning portfolio strategy. To support the development of your own successful portfolio strategy, Pharma Intelligence invites you to watch our webinar: “Where is the pharma industry maximizing value?”, filmed on Tuesday May 23, 2017, presented by Datamonitor Healthcare Principal Analyst, Amanda Micklus.

 

This webinar focuses on the state of the pharma industry regarding long-term portfolio planning from the R&D stage through externalization and commercialization. Covered topics include:

 

Business development trends, including - internal R&D spending (including productivity measurements). What are the factors contributing to the projected sharp CAGR decline through 2020? Who shows most success with new product launches, and why?

 

Licensing and deal-making - How does pharma complement internal R&D with external business development deals? Find out by volume, value, phase, and therapy area.

 

Revenue trends – How do we view R&D investment and licensing/deal-making through the lens of revenue? Compare companies in Big Pharma, Mid Pharma, and Japan Pharma in terms of internal R&D product revenue versus that from external products.

 

Read also

  • HBW Insight: Health, Beauty and Wellness, Generics Bulletin,...

    Pharma Intelligence Launches Alexa Skill

    Keep up with topics you care about in Pharma and Medtech with the new Alexa Skill from Informa Pharma Intelligence. Access daily news briefings to stay up to date with the latest news, right from your Alexa smartphone app!

    Topics $name $name $name

  • Scrip: industry news and insights, Datamonitor Healthcare: d...

    Top 10 Best-Selling Drugs of 2019

    By Stephanie Yip

    In 2019, the 10 most lucrative medicines generated combined global sales of $92.5B. Scrip provides insight into these top sellers and the companies behind them, as well US dynamics, global sales forecasts and lifecycle data, with complementary market analysis from Datamonitor Healthcare on diseases targeted, indications, and more.

    Topics Drug Review Diseases

  • Scrip: industry news and insights, Datamonitor Healthcare: d...

    Top 10 Best-Selling Drugs of 2019

    By Stephanie Yip

    In 2019, the 10 most lucrative medicines generated combined global sales of $92.5B. Scrip provides insight into these top sellers and the companies behind them, as well US dynamics, global sales forecasts and lifecycle data, with complementary market analysis from Datamonitor Healthcare on diseases targeted, indications, and more.

    Topics Drug Review Diseases

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: